^(89)Sr治疗晚期前列腺癌伴骨转移的临床疗效观察  

Strontium^(89) in palliative therapy for late-stage prostate cancer with bone metastases

作　　者：吴波[1] 

机构地区：[1]沈阳市第五人民医院泌尿外科,辽宁沈阳110023

出　　处：《海南医学》2010年第10期17-18,12,共3页Hainan Medical Journal

摘　　要：目的评价89Sr治疗前列腺癌伴骨转移的临床疗效。方法对前列腺癌骨转移伴骨痛的30例患者,入院后行双侧睾丸切除术+89Sr治疗。89Sr采取静脉给药,剂量1.48-2.22MBq(40-60μCi)/kg。随访分析临床疗效。结果骨转移性疼痛缓解总有效率为90.0%,36.7%的患者完全缓解;骨痛缓解开始出现时间3-18d,平均10d;骨痛缓解维持时间3-11个月,平均6个月;部分患者治疗1周后白细胞和血小板有所下降。白细胞平均约降低20.8%,血小板平均约降低29.1%。3个月时血象可基本恢复正常。6个月后随访21例骨显像,治疗后42.9%(9例)骨转移灶数目较治疗前明显减少,38.1%(8例)稳定,19.0%(4例)加重,出现新的骨转移灶。结论 89Sr治疗能有效抑制骨转移,缓解骨痛,改善生存质量,不良反应轻,是前列腺癌骨转移性疼痛的一种治疗方法 。Objective To study the clinical efficacy of strontium89 （Sr89） in palliative therapy for late-stage prostate cancer with bone metastases.Methods 30 patients with painful bone metastases of prostate cancer received bilateral orchectomy and intravenous injection of Sr89 at the dose of 1.48-22.22MBq （40-60μCi） /kg.Then we analysed the clinical effect by follow-up.Results After the treatment of Sr89,pain alleviated in 90.0%,with an absolute palliation rate of 36.7%.Pain palliation started at 3-18 days and lasted for 3-11 months.The WBC count decreased 20.8% of the patients averagely,with PLT count decreased 29.1%.They can return to mormal after 3 months.6 months later,21 were followed-up by single-Photon Emission Computed Tomography,and found that 9（42.9%） of them exhibited an obvious decrease in the number of metastases,8 （38.1% ） stabilized and only 4 （19.0% ） deteriorated.Conclusion Sr89,capable of inhibiting bone metastasis,relieving pain and improving the quality of life of patients with few adverse effects,can be used as a desirable palliative therapy for late-stage prostate cancer with bone metastases.

关 键 词：89Sr 前列腺癌 骨转移性疼痛 

分 类 号：R737.25[医药卫生—肿瘤]